MPN Childhood Registry

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age0-17
SponsorUniversity of Erlangen-Nürnberg Medical School

About this trial

Myeloproliferative neoplasms (MPNs) are caused by defects in blood cell production. This leads to an overproduction of mature cells, such as red blood cells or platelets. As a result, clinical symptoms and complications can develop. Circulatory disorders and resulting pain symptoms, such as headaches, are the most prominent. Furthermore, blood clotting disorders can occur, leading to vascular occlusions or bleeding. Over a longer period, bone marrow transformation into fibrous tissue or the development of acute leukemia can occur, resulting in even more serious complications.

In the vast majority of cases, MPNs are diagnosed in older adults. These diagnoses are extremely rare in children and adolescents. Therefore, clinical and genetic characteristics, treatment options, and outcomes in pediatric patients with MPNs are insufficiently described, and only limited data are available for standardizing diagnostic and therapeutic approaches for MPNs in childhood and adolescence. Recommendations and guidelines from the adult field, which have largely been adopted and applied to children and adolescents, do not adequately address the specific needs of patients in childhood and adolescence. To gain more insights into MPN during this early, vulnerable phase of life, we have established a nationwide registry in Germany that systematically collects data from children and adolescents with MPN.

The registry focuses particularly on the scientific analysis of the biological characteristics and differences of MPN in children and adolescents compared to adults.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Newly diagnosed PV, ET, PMF or pHES

Age < 18 years (up to 17 years and 365 days) at the day of diagnosis

Patient treated in a participating center

Written informed consent to registry participation

Disqualifiers

None

Trial population

Children and adolescents below the age of 18 years diagnosed with Myeloproliferative Neoplasms

Trial design

Design model

Cohort

Time perspective

Other

Treatments tested in this trial

  • Observation

    Other intervention

    Observation

Treatment groups

500 Participants
are divided into 1 treatment group
Group A: Childhood MPN1 intervention

Trial outcomes

Primary outcomes

1

Incidence and epidemiology

Incidence and epidemiology of PV, ET, PMF and pHES in children and adolescents through systematic inclusion of these patients in a national population-based registry

Time frame
15 years
2

Characterization

Characterization of clinical, hematologic, genetic and cytogenetic features of children and adolescents with PV, ET, PMF and pHES

Time frame
15 years
3

Risk identification

Identification of pediatric patients with high risk of complications and disease progression and transformation into acute myeloid leukemia (AML)

Time frame
15 years
4

Improvement of therapy

Improvement of the therapy for children and adolescents with MPN by discussing treatment options with the treating centers and tailor therapy to the specific and individual needs of pediatric patients

Time frame
15 years

Secondary outcomes

1

Preparation of international studies

Preparation of future international collaborative prospective studies focusing on the optimization and standardization of childhood MPN-diagnosis and treatment

Time frame
15 years
2

Development of a biobank

Development of a biobank system of pediatric patients with MPN

Time frame
15 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.